Clinical biomarkers in drug discovery and development

Nature Reviews Drug Discovery

Volumn 2, Issue 7, 2003, Pages 566-580

  Frank, Richard ^a   Hargreaves, Richard ^b  

^a Merck and Co ^*

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CISPLATIN; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; MIDAZOLAM; NEUROKININ 1 RECEPTOR; NEW DRUG; REMIFENTANIL; TAU PROTEIN;

ANALGESIC ACTIVITY; ANGIOCARDIOGRAPHY; CANCER; CAROTID ARTERY OBSTRUCTION; CORONARY ARTERY OBSTRUCTION; DEGENERATIVE DISEASE; DIAGNOSTIC VALUE; DRUG DESIGN; DRUG INDICATION; DRUG RESPONSE; DRUG TARGETING; GENOMICS; HUMAN; INTRAVASCULAR ULTRASOUND; MEDICAL DECISION MAKING; MENTAL DISEASE; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PATIENT CODING; POSITRON EMISSION TOMOGRAPHY; PRIMARY PREVENTION; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REVIEW; RISK ASSESSMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANQUILIZING ACTIVITY; ALZHEIMER DISEASE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GENE EXPRESSION PROFILING; HEART DISEASE; NEOPLASM; PHARMACOGENETICS; PROTEOMICS;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DRUG DESIGN; GENE EXPRESSION PROFILING; HEART DISEASES; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; PHARMACOGENETICS; PROTEOMICS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0038004636     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1130     Document Type: Review

References (168)

1. Roberts, S. A. Drug metabolism and pharmacokinetics in drug discovery. Curr. Opin. Drug Discov. Devel. 6, 66-80 (2003).
2. Laska, D. et al. Characterization and application of a vinblastine-selected Caco-2 cell line for evaluation of P-glycoprotein. In Vitro Cell. Devel. Biol. Anim. 38, 401-410 (2002).
3. Yuan, R. P. et al. In vitro metabolic interaction studies: Experience of the Food and Drug Administration. Clin. Pharmacol. Ther. 66, 9-15 (1999).
4. Schadt, E. E., Monks, S. A. & Friend, S. H. A new paradigm for drug discovery: integrating clinical genetic, genomic and molecular phenotype data to identify drug targets. Biochem. Soc. Trans. 31, 437-443 (2003).
5. van de Vijver, M. et al. A gene expression signature as a predictor of survival in breast cancer N. Engl. J. Med. 347, 1999-2009 (2002).
6. Lesko, L. J. & Woodcock, J. Pharmacogenomic-guided drug development: Regulatory perspective. Pharmacogenomics J. 2, 20-24 (2002).
7. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) & (CBER). Guidance for Industry and Reviewers Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers (2002).
8. Rolan, P., Atkinson, A. & Lesko, L. J. Use of biomarkers from drug discovery through clinical practice: Report of the Ninth European Federation of Pharmaceutical Sciences Conference on optimizing drug development. Clin. Pharm. Ther. 73, 284-291 (2003).
9. De Gruttola, V. G. et al. Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health Workshop. Control. Clin. Trials 22, 485-502 (2001).
10. De Meyer, G. & Shapiro, F. Biomarker development: The road to clinical utility. Curr. Drug Discov. 12, 23-27 (2003).
11. Atkinson, A. J., Jr. et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 80-95 (2001).
12. Prentice, R. L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat. Med. 8, 431-440 (1989).
13. Sormani, M. P., Bruzzi, P., Comi, G. & Filippi, M. MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. Neurology 58, 417-421 (2002).
14. Lin, D. Y., Fleming, T. R. & Be Gruttola, V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat. Med. 16, 1515-1527 (1997).
15. Flandre, P & Saidi, Y. Estimating the proportion of treatment effect explained by a surrogate marker. Stat. Med. 16, 1515-1527 (1997).
16. Cowles, M. K. Bayesian estimation of the proportion of treatment effect captured by a surrogate marker. Stat. Med. 21, 811-834 (2002).
17. Buyse, M. & Molenberghs, G. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 54, 1014-1029 (1998).
18. Congress, O. h. f. Senate Bill 830 Food and Drug Administration Modernization Act of 1997. 10 (1997).
19. Temple, R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA. 282, 790-795 (1999).
20. Alonso, A., Geys, H., Molenberghs, G. & Vangeneugden, T. Investigating the criterion validity of psychiatric symptom scales using surrogate marker validation methodology. J. Biopharm. Stat. 12, 161-178 (2002).
21. Streiner, D. & Norman, G. Health Measurement Scales: A Practical Guide to Their Development and Use (Oxford University Press, Oxford, 1995).
22. Swanson, B. N. Delivery of high-quality biomarker assays. Dis. Markers 18, 47-56 (2002).
23. Bossuyt, P. & Reitsma, J. B. The STARD Initiative. Lancet 361, 71 (2003).
24. Crum, W. R., Scahill, R. I. & Fox, N. C. Automated hippocampal segmentation by regional fluid registration of serial MRI: Validation and application in Alzheimer's disease. Neuroimage 13, 847-855 (2001).
25. Rolan, P. The contribution of clinical pharmacology surrogates and models to drug development - a critical appraisal. Br. J. Clin. Pharmacol. 44, 219-225 (1997).
26. Wesnes, K., Simpson, P. & Kidd, A. An investigation of the range of cognitive impairments induced by scopolamine 0.6 mg s. c. Hum. Psychopharmacol. 3, 27-41 (1988).
27. Kitagawa, H. et al. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 28, 542-551 ((2003)).
28. Huestis Marilyn, A. et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch. Gen. Psychiatry 58, 322-328 (2001).
29. Lonn, E. The use of surrogate endpoints in clinical trials: Focus on clinical trials in cardiovascular diseases. Pharmacoepidemiol. Drug Saf. 10, 497-508 (2001).
30. Daniels, M. J. & Hughes, M. D. Meta-analysis for the evaluation of potential surrogate markers. Stat. Med. 16, 1965-1982 (1997).
31. Gail, M. H., Pfeiffer, R., van Houwelingen, H. C. & Carroll, R. J. On meta-analytic assessment of surrogate outcomes. Biostat. 1, 231-246 (2000).
32. Becker, N. G. & Marschner, I. C. Advances in medical statistics arising from the AIDS epidemic. Stat. Methods Med. Res. 10, 117-140 (2001).
33. Lesko, L. J. & Atkinson, A. J. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies. Ann. Rev. Pharmacol. Toxicol. 41, 347-366 (2001).
34. Pearson, T A. et al. Markers of inflammation and cardiovascular disease application to clinical and public health practice - A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 107, 499-511 (2003).
35. Fleming, T. R. & DeMets, D. L. Surrogate end points in clinical trials: are we being misled?[comment]. Ann. Intern. Med. 125, 605-613 (1996).
36. Collburn, W. A. Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development. J. Clin. Pharmacol. 40, 1419-1427 (2000).
37. Morris, J. C. et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch. Neurol. 58, 397-405 (2001).
38. 18F)fluoro-2-deoxy-D-glucose/ positron-emission tomography (FDG/PET). Proc. Natl Acad. Sci. USA 98, 10966-10971 (2001).
39. Jack, C. R. et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 55, 484-489 (2000).
40. Hodis, H. N. et al. Estrogen in the prevention of atherosclerosis - a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 135, 939-953 (2001).
41. Choudhury, R. P., Fuster, V., Badimon, J. J., Fisher, E. A. & Fayad, Z. A. MRI and characterization of atherosclerotic plaque: Emerging applications and molecular imaging. Arterioscler. Thromb. Vasc. Biol. 22, 1065-1074 (2002).
42. Yuan, C. P. et al. Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke. Circulation 105, 181-185 (2002).
43. Corti, R. et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow up by high resolution noninvasive magnetic resonance imaging. Circulation 106, 2884-2887 (2002).
44. Stefanadis, C. M. D. et al. Thermal heterogeneity within human atherosclerotic coronary arteries detected in vivo: a new method of detection by application of a special thermography catheter. Circulation 99, 1965-1971 (1999).
45. 18f]-fluorodeoxyglucose positron emission tomography. Circulation 105, 2708-2711 (2002).
46. De Franco, A. C. & Nissen, S. E. Coronary intravascular ultrasound: implications for understanding the development and potential regression of atherosclerosis. Am. J. Cardiol. 88, 7M-20M (2001).
47. Nissen, S. Application of intravascular ultrasound to characterize coronary artery disease and assess the progression or regression of atherosclerosis. Am. J. Cardiol. 89, 24B-31B (2002).
48. Nieman, K. et al. Reliable noninvasive coronary angiography with fast submillimeter multislice spiral computed tomography. Circulation 106, 2051-2054 (2002).
49. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994).
50. Heart Protection study collaborative group (2002) MRC/BHF Heart Protection study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo controlled trial. Lancet 360, 7-22 (2002).
51. Taubes, G. Cardiovascular disease: Does inflammation cut to the heart of the matter? Science 296, 242-245 (2002).
52. Ricker, P. M., Hennekens, C. H., Buring, J. E. & Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836-843 (2000).
53. van der Wal, A. C. et al. Recent activation of the plaque immune response in coronary lesions underlying acute coronary syndromes. Heart 80, 14-18 (1998).
54. Albert, M. A., Danielson, E., Rifai, N. & Ricker, P. M. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 286, 64-70 (2001).
55. Szalai, A., J., Cooper, G., S., McCrory, M., A. & Kimberly, R., P. Association between a GT-repeat polymorphism in the intron of the C-reactive protein (CRP) gene and plasma CRP. FASEB J. 15, A685 (2001).
56. Sides, G. D. QT interval prolongation as a biomarker for Torsades de Pointes and sudden death in drug development. Dis. Markers 18, 57-62 (2002).
57. Herman, E. H. et al. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother. Pharmacol. 48, 297-304 (2001).
58. Schaefer, P. W. et al. Predicting cerebral ischemic infarct volume with diffusion and perfusion MR imaging. Am. J. Neuroradiol. 23, 1785-1794 (2002).
59. Wintermark, M. Prognostic accuracy of cerebral blood flow measurement by perfusion computed tomography, at the time of emergency room admission, in acute stroke patients. Ann. Neurol. 51, 417-432 (2002).
60. 18F]dopa PET. J. Neurol. Neurosurg. Psychiatry 64, 314-319 (1998).
61. Du, A. T. et al. Atrophy rates of entorhinal cortex in AD and normal aging. Neurology 60, 481-486 (2003).
62. Grundman, M. et al. Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J. Mol. Neurosci. 19, 23-27 (2002).
63. Jacobs, L. D. et al. Intramuscular interferon-β-1 a therapy initiated during a first demyelinating event in multiple sclerosis. N. Engl. J. Med. 343, 898-904 (2000).
64. Jack, C. R. et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 60, 253-260 (2003).
65. Fox, N. C., Cousens, S., Scahill, R., Harvey, R. J. & Rossor, M. N. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease - power calculations and estimates of sample size to detect treatment effects. Arch. Neurol. 57, 339-344 (2000).
66. Fox, N. C. et al. Presymptomatic hippocampal atrophy in Alzheimers disease - a longitudinal MRI study. Brain 119, 2001-2007 (1996).
67. Thompson, P. M. et al. Dynamics of gray matter loss in Alzheimer's disease. J. Neurosci. 23, 994-1005 (2003).
68. Silverman, D., H. S. et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286, 2120-2127 (2001).
69. Zhuang, Z. P. et al. Structure-activity relationship of imidazo. J. Med. Chem. 46, 237-243 (2003).
70. Cagnin, A., Gerhard, A. & Banati, R. B. In vivo imaging of neuroinflammation. Eur. Neuropsychopharmacol. 12, 581-586 (2002).
71. Frank, R. et al. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the Biological Markers Working Group; NA Initiative on Neuroimaging in Alzheimers Disease. Neurobiol. Aging 24 (in the press).
72. Sunderland, T. et al. Decreased β-amyloid 1-42 and increased Tau levels in cerebrospinal fluid of patients with Alzheimer's disease. JAMA 289, 2094-2103 (2003).
73. Gurwitz, D. Targeting Alzheimer's disease: Is there a light at the end of the tunnel? Drug Dev. Res. 56, 45-48 (2002).
74. Selkoe, D. J. Alzheimer's disease: Genes, proteins, and therapy. Physiol. Rev. 81, 741-766 (2001).
75. Morris, J. C. & Price, J. L. Pathologic correlates of non-demented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J. Mol. Neurosci. 17, 101-118 (2001).
76. Petersen, R. C. et al. Current concepts in mild cognitive impairment. Arch. Neurol. 58, 1985-1992 (2001).
77. Trojanowski, J. Q. Alzheimer's disease centers and the dementias of aging program of the national institute on aging: A brief overview. J. Alzheimer's Dis. 3, 249-251 (2001).
78. Duffy, M. J. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin. Chem. 47, 624-630 (2001).
79. Grizzle, W. E., Manne, U., Jhala, N. C. & Weiss, H. L. Molecular characterization of colorectal neoplasia in translational research. Arch. Pathol. Lab. Med. 125, 91-98 (2001).
80. Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl Cancer Inst. 92, 205-216 (2000).
81. Hopper, K. D., Singapuri, K. & Finkel, A. Body CT and oncologic imaging. Radiology 215, 27-40 (2000).
82. Yankelevitz, D. F., Reeves, A. P., Kostis, W. J., Zhao, B. & Henscke, C. I. Small pulmonary nodules: volumetrically determined growth rates based on CT evaluation. Radiology 217, 251-256 (2000).
83. Henschke C. I. et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 354, 99-105 (1999).
84. Gupta, N. C., Graeber, G. M., Rogers, J. S. & Bishop, H. A. Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. Ann. Surgery. 229, 286-291 (1999).
85. Van den Abbeele, A. D. & Badawi, R. D. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur. J. Cancer 38, S60-65 (2002).
86. Eubank, W. B. et al. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics 22, 5-17 (2002).
87. Mortimer, J. E. et al. Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer. J. Clin. Oncol. 19, 2797-2803 (2001).
88. Shields, A. et al. Imaging proliferation in vivo with [F-18] and positron emission tomography. Nature Med. 4, 1334-1336 (1998).
89. Eriksson, B. et al. The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann. NY Acad. Sci. 970 159-169 (2002).
90. Mankoff, D. A., Dehdashti, F. & Shields, A. F. Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia 2, 71-88 (2000).
91. 68Germanium attenuation correction. Mol. Imag. Biol. 4, 399-409 (2002).
92. Beyer, T., Townsend, D. W. & Blodgett, T. M. Dual-modality PET/CT tomography for clinical oncology. Q. J. Nucl. Med. 46, 24-34 (2002).
93. Antoch, G. et al. Whole-body positron emission tomography-CT: Optimized CT using oral and IV contrast materials. Am. J. Roentgenol. 179, 1555-1560 (2002).
94. Masood, S. Standardization of immunobioassays as surrogate endpoints. J. Cell. Biochem. 19, S28-S35 (1994).
95. Grouse, L. H., Munson, P. J. & Nelson, P. S. Sequence databases and microarrays as tools for identifying prostate cancer biomarkers. Urology 57, 154-159 (2001).
96. Scherf, U. et al. A gene expression database for the molecular pharmacology of cancer Nature Genet. 24, 236-244 (2000).
97. Shipp, M. A. et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Med. 8, 68-74 (2002).
98. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001).
99. Bittiner, M. et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536-540 (2000).
100. Van't Veer, L. J. & De Jong, D. The microarray way to tailored cancer treatment. Nature Med. 8, 13-14 (2002).
101. Di Leo, A. et al. Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002. Int. J. Clin. Oncol. 7, 245-53 (2002).
102. Rosenwald, A. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 1937-1947 (2002).
103. Simon, R., Radmacher, M. D., Dobbin, K. & McShane, L. M. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J. Natl Cancer Inst. Cancer Spectrum 95, 14-18 (2003).
104. Quackenbush, J. Computational analysis of microarray data. Nature Rev. Genet. 2, 418-427 (2001).
105. Raap, D. A. V. D. K., LD. Mini-review: selective serotonin reuptake inhibitors and neuroendocrine function. Life Sci. 65 (1999).
106. Grillon, C., Codova, J., Levine, L. R. & Morgan, C. A. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY 354740) in the fear potentiated startle paradigm in humans. Psychopharmacology 2003 April 23 (DOI: 10.1007/s00213-003-1444-8).
107. Riba, J. et al. Differential effects of alprazolam on the baseline and fear potentiated startle reflex in humans: A dose response study. Psychopharmacology 157, 358-367 (2001).
108. Guimares, F. S. et al. A simple simulated public speaking test for evaluating anxiolytic drugs. Braz. J. Med. Biol. Res. 22, 1083-1089 (1989).
109. Abelson, J. L., Weg, J. G., Nesse, R. M. & Curtis, G. C. Neuroendocrine responses to laboratory panic: cognitive intervention in the doxapram model. Psychoneuroendocrinology 21, 375-390 (1996).
110. Liebowitz, M. R. et al. Effects of intravenous diazepam pretreatment on lactate-induced panic. Psychiatry Res. 58, 127-138 (1995).
111. Valencia, A. M., N. A., Nascimento, I., Zin, W. A. & Versiani, M. Carbon dioxide test as an additional clinical measure of treatment response in panic disorder. Arq. Neuropsiquiatr. 60, 358-361 (2002).
112. de Visser, S. J. et al. Biomarkers for the effects of benzodiazepines in healthy volunteers. Br. J. Clin. Pharmacol. 55, 39-50 (2003).
113. Lesko, L. J., Rowland, M., Peck, C. C. & Blaschke, T. F. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Eur. J. Pharm. Sci. 10, iv-xiv (2000).
114. Cherry, S. R. & Gambhir, S. S. Use of positron emission tomography in animal research. ILAR J. 42, 219-232 (2001).
115. 1 Receptors in the living human brain using positron emission tomography. J. Clin. Psychiatry 63, 18-24 (2003).
116. Chawla, S. P. et al. Establishing the dose of the oral NK-1 antagonist MK-869 for chemotherapy-induced nausea and vomiting. Am. Soc. Clin. Oncol. A1527 (2001).
117. Bradley, M. M., Cuthbert, B. N. & Lang, P. J. Picture media and emotion - effects of a sustained affective context. Psychophysiology 33, 662-670 (1996).
118. Cuthbert, B. N., Bradley, M. M. & Lang, P. J. Probing picture perception - activation and emotion. Psychophysiology 33, 103-111 (1996).
119. Sheline, Y. I. et al. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: An fMRI study. Biol. Psychiatry 50, 651-658 (2001).
120. Gross, J. J. & Levenson, R. W. Emotion elicitation using films. Cognition Emotion 9, 87-108 (1995).
121. Rottenberg, J., Gross, J. J., Wilhelm, F. H. & Gotlib, I. H. Crying threshold and intensity in major depressive disorder. J. Abnorm. Psychol. 111, 302-312 (2002).
122. Yamasaki, H., LaBar, K. S. & McCarthy, G. Dissociable prefrontal brain systems for attention and emotion. Proc. Natl Acad. Sci. USA 99, 11447-11451 (2002).
123. Ploghaus, A. et al. Exacerbation of pain by anxiety is associated with activity in a hippocampal network. J. Neurosci. 21, 9896-9903 (2001).
124. Wise, R. G. et al. Combining fMRI with a pharmacokinetic model to determine which brain areas activated by painful stimulation are specifically modulated by remifentanil Neuroimage 16, 999-1014 (2002).
125. Borsook, D. & Bercerra, L. Utilizing brain imaging for analgesic drug development. Curr. Opin. Investig. Drugs 3, 1342-1347 (2002).
126. Peterfy, C. G. Imaging of the disease process. Curr. Opin. Rheumatol. 14, 590-596 (2002).
127. Rudin, M. & Weissleder, R. Molecular imaging in drug discovery and development. Nature Rev. Drug Discov. 2, 123-131 (2003).
128. Santos-Rosa, H. et al. Active genes are tri-methylated at K4 of histone H3. Nature 419, 407-411 (2002).
129. Weiss, S. T., Silverman, E. K. & Palmer, L. J. Case-control association studies in pharmacogenetics. Pharmacogenomics J. 1, 157-8 (2001).
130. Kiberstis, F. & Roberts, L. It's not just the genes. Science 296, 685 (2002).
131. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) & (CBER). Guidance for Industry In Vivo Drug Metabolism/Drug Interaction Studies - Study Design, Data Analysis, and Recommendations for Dosing and Labeling (1999).
132. Venkatakrishnan, K., Von Moltke, L. L. & Greenblatt, D. J. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes P450 to human liver microsomes: Studies on amitriptyline as a model substrate. J. Pharmacol. Exp. Ther. 297, 326-337 (2001).
133. Koukouritaki, S. B., Simpson, P., Yeung C. K., Rettie, A. E. & Hines, R. N. Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr. Res. 51, 236-243 (2002).
134. Sonnier, M. & Cresteil, T. Delayed ontogenesis of cyp1a2 in the human liver. Eur. J. Biochem. 251, 893-898 (1998).
135. Leeder, J. S. Pharmacogenetics and pharmacogenomics. Pediatr. Clin. North Am. 48, 765-781 (2001).
136. Hoggard, P. G. & Back, D. J. Intracellular pharmacology of nucleoside analogues and protease inhibitors: Role of transporter molecules. Curr. Opin. Infect. Dis. 15, 3-8 (2002).
137. SenGupta Dhruba, J. et al. A single glycine mutation in the equilibrative nucleoside transporter gene, hENT1, alters nucleoside transport activity and sensitivity to nitrobenzylthioinosine. Biochemistry 41, 1512-1519 (2002).
138. Tanaka, C., Kowai, R. & Rowland, M. Physiologically based pharmacokinetics of cyclosporine a: reevaluation of dose-nonlinear kinetics in rats. J. Pharmacokinet. Biopharm. 27, 597-623 (1999).
139. Slapak, C., A., Dahlheimer, J. & Piwnica-Worms, D. Reversal of multidrug resistance with LY335979: Functional analysis of P-glycoprotein-mediated transport activity and its modulation in vivo. J. Clin. Pharmacol. 41, 29S-38S (2001).
140. Conrad, S. et al. A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 12, 321-330 (2002).
141. Dresser, G. K., Schwarz, U. I., Wilkinson, G. R. & Kim, R. B. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin. Pharmacol. Ther. 73, 41-50 (2003).
142. Unadkat, J. D., Link, J., Muzi, M., Dupuis, A. & Mankoff, D. In vivo P-glycoprotein (P-gp) transport activity in the pregnant M. nemestrina as measured by biodistribution of (11C)-verapamil and positron emission tomography (PET). J. Med. Primatol. 31, 308 (2002).
143. Ballinger, J. R. Tc-99m-tetrofosmin for functional imaging of P-glycoprotein modulation in vivo. J. Clin. Pharmacol. (2001).
144. Wandel, C., Kim, R., Wood, M. & Wood, A. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 96, 913-920 (2002).
145. 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl Acad. Sci. 97, 10483-10488 (2000).
146. Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C. & Liotta, L. A. Clinical proteomics translating benchside promise into bedside reality. Nature Rev. Drug Discov. 1, 683-695 (2002).
147. Kantor, A. B. Comprehensive phenotyping and biological marker discovery. Dis. Markers 18, 91-97 (2002).
148. Walton, I. D. et al. A microvolume laser scanning cytometry platform for biological marker discovery. Proc. SPIE 3926, 192-201 (2000).
149. Wang, W. et al. Quantification of proteins and metabolites by mass spectrometry without isotopic labeling or spiked standards. Submitted for publication (2003).
150. Crabb, J. W. et al. Drusen proteome analysis: An approach to the etiology of age-related macular degeneration. Proc. Natl Acad. Sci. USA 99, 14682-14687 (2002).
151. Brindle, J. T. et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using H-1-NMR-based metabonomics. Nature Med. 8, 1439-1444 (2002).
152. Petricoin, E. F. et al. Use of proteomic patterns in serum to identify ovarian cancer Lancet 359, 572-577 (2002).
153. McDonald, W. H. & Yates, J. R. Shotgun proteomics and biomarker discovery. Dis. Markers 18, 99-105 (2002).
154. Renwick, A. G. & Walton, K. The use of surrogate endpoints to assess potential toxicity in humans. Toxicol. Lett. 120, 97-110 (2001).
155. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) & Center for Biologics Evaluation and Research (CBER). Guidance for industry and Reviewers Estimating the Safe Starting Dose in Clinical Trials for Therapeutics In Adult Healthy Volunteers (2002).
156. Kantor, A. B. et al. Biomarker discovery by comprehensive phenotyping for autoimmune diseases. Clin. Immunol. (in the press).
157. den Broeder, A. A. et al. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: Effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann. Rheum. Dis. 61, 311-318 (2002).
158. Neuhold, L. A. et al. Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J. Clin. Invest. 107, 35-44 (2001).
159. Cunnane, G., FitzGerald, O., Beeton, C., Cawston, T. E. & Bresnihan, B. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum. 44, 2263-2274 (2001).
160. Bayliss, M. T., Hutton, S., Hayward, J. & Maciewicz, R. A. Distribution of aggrecanase (ADAMts 4/5) cleavage products in normal and osteoarthritic human articular cartilage: The influence of age, topography and zone of tissue. Osteoarth. Cartil. 9, 553-560 (2001).
161. Armstrong, B. & Doll, R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int. J. Cancer 15, 617-631 (1975).
162. Wakeland, E. K., Liu, K., Graham, R. R. & Behrens, T. W. Delineating the genetic basis of systemic lupus erythematosus. Immunity 15, 397-408 (2001).
163. Cummings, D. E. & Schwartz, M. W. Genetics and pathophysiology of human obesity. Annu. Rev. Med. 54, 453-457 (2003).
164. Townsend, D. W. & Beyer, T. A combined PET/CT scanner: the path to true image fusion. Br. J. Radiol. 75, S24-S30 (2002).
165. Katz, R., Wagner, H. N., Fauntleroy, M., Kuwert, T. & Frank, R. The use of imaging as biomarkers in drug development: Regulatory issues worldwide. J. Clin. Pharmacol. 41, 118S-126S (2001).
166. Schwaiger, M. Functional imaging for assessment of therapy. Br. J. Radiol. 75, S67-S73 (2002).
167. Ferguson, S. M. Licensing and distribution of research tools: National institutes of health perspective. J. Clin. Pharmacol. 110S-112S (2001).
168. Esmond, R. W. The patenting of tools for drug discovery and development. J. Clin. Pharmacol. 112S-115S (2001).